Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The only material change disclosed is a reduction in shareholding by a senior executive:
- Executive: Mr. J R Stéphenne
- Transaction: Sale of 20,000 Ordinary shares
- Price: £13.35 per share
- Date: May 19, 2011
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the share sale in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total shareholding of Mr. J R Stéphenne post-transaction to assess remaining exposure.
- Confirm the market price of GSK shares on May 19, 2011, to contextualize the £13.35 sale price.
- Review subsequent filings to determine if this sale was part of a pre-arranged trading plan or an isolated event.